Developer docs
API playgroundTry for free, no card

Search company profiles

Fangzhou

Full company profile

uuid02m7k6e

Namestring
Fangzhou
Legal namestring
Fangzhou Inc.
Websiteurl
jianke.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
online pharmacy retail, chronic disease management, telemedicine consultations, AI healthcare platform, pharmaceutical e-commerce
Industry3 codes
PRIMARYHLALAIAA
DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
NAICS code2 codes
  • Pharmacies and Drug Retailers456110
  • Pharmacies and Drug Retailers45611
SIC code2 codes
  • Retail-Drug Stores And Proprietary Stores5912
  • Services-Health Services8000
Product category
Online Pharmacy and Digital Healthcare
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Online Pharmacy Retail
TypeTransaction Fee
Description

Direct-to-consumer online pharmacy sales through jianke.com platform. Customers purchase prescription and OTC medications, health products, medical devices, and supplements. Revenue generated from product sales with pricing varying by medication type and brand.

financialcontent.com
2Healthcare Services
TypeSubscription Recurring
Description

Telemedicine consultation services connecting registered users with physicians. Platform facilitates online consultations, medication guidance, and health management services to registered users.

financialcontent.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Individual product pricing varies by medication type and manufacturer
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products range from OTC medications to prescription drugs. Example prices include: 眩晕宁片 ¥25.20, 耳聋通窍丸 ¥20.90, 柴胡舒肝丸 ¥10.00, 胆舒软胶囊 ¥9.90, 舒肝片 ¥32.80

GTM typeB2C
B2C
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

Fangzhou operates a direct-to-consumer online pharmacy and digital healthcare platform selling prescription and OTC medications, health supplements, and medical devices through jianke.com. The platform provides telemedicine consultations with registered physicians and uses its proprietary XS LLM AI platform for chronic disease management. It serves over 59.8 million registered users and 282,000 physicians across China, primarily focused on chronic care patients requiring ongoing medication and monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue growth of 22.2% YoY reaching RMB 1.8245 billion in H1 2026
+2 more records
Product overview1 text field

Fangzhou Inc. operates as a healthcare AI company with two main offerings: (1) AI-Powered Healthcare Solutions centered on the XS LLM Platform that automates patient and physician workflows for chronic disease management, and (2) 方舟健客 (Fangzhou Jianke) - a B2C online pharmacy ecosystem comprising the jianke.com e-commerce platform and the 健客医生 mobile app. The AI platform powers clinical decision support and healthcare automation, while the pharmacy platform provides online medication sales, health consultations, and patient monitoring services. The company serves over 59.8 million registered users with 282,000 registered physicians on its platform.

Product and service2 records
1Fangzhou Jianke Online Pharmacy (方舟健客网上药店)
CategoryOnline pharmacy e-commerce
Description

B2C online pharmacy platform where individual consumers nationwide can search, purchase, and receive prescription and OTC medications, health supplements, and medical devices, with pharmacist consultation support and prescription upload functionality.

2Jianke Doctor (健客医生)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-28
Description

Fangzhou and Tencent Healthcare launched an AI-powered chronic disease management solution combining Fangzhou's clinical expertise with Tencent's cloud infrastructure. The platform enables personalized patient monitoring and early complication detection, streamlining clinical workflows and reducing professional workload while improving patient outcomes within China's chronic care ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-07
Description

Fangzhou and Novo Nordisk launched an initiative for AI-powered diabetes and weight management solutions at the 8th China International Import Expo (CIIE) in Shanghai. Fangzhou was recognized as an 'Outstanding Strategic Health Ecosystem Partner' for digital innovation in chronic disease management. The strategic partnership aims to integrate Fangzhou's AI infrastructure with Novo Nordisk's therapies to shift from disease-focused treatment to proactive health management.

3Multiple Pharmaceutical Manufacturers
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fangzhou has established strategic partnerships with major pharmaceutical manufacturers to ensure direct supply of authentic products. These partnerships enable competitive pricing, product exclusivity, and reliable supply chain management. The company claims to have agreements with numerous large-scale drug manufacturers for direct procurement.

jianke.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1JD Health International
TypeDirect peer
Description

Hong Kong-listed Chinese online pharmacy and healthcare services platform with integrated telemedicine and chronic-disease management. Closest direct competitor to Fangzhou given overlapping DTC pharmacy model, AI-enabled healthcare ambitions and China-only footprint.

TypeDirect peer
Description

HKEX-listed arm of Alibaba operating China's largest healthcare e-commerce platforms alongside telehealth and chronic-care services. Competes head-on with Fangzhou's jianke.com on drug retail assortment, pricing and AI-driven consumer health experiences.

TypeDirect peer
Description

China-based online healthcare platform offering telemedicine consultations, chronic-care management and online pharmacy under the Ping An ecosystem. Highly relevant given comparable AI-enabled chronic-care strategy and integrated physician network.

TypeDirect peer
Description

Major Chinese digital healthcare platform combining hospital appointment booking, telemedicine and chronic-disease management. Overlaps with Fangzhou in AI chronic care, physician network and DTC patient services within China.

5Dingdang Health (Dingdang Kuaiyao)
TypeDirect peer
Description

China-focused online pharmacy with rapid-delivery prescription drug network and AI-powered chronic-care capabilities. Directly comparable to Fangzhou on DTC online pharmacy model and condition-specific digital health programs.

TypeDirect peer
Description

NASDAQ-listed Chinese digital healthcare platform offering online pharmacy, B2B drug distribution and chronic-disease management. Comparable to Fangzhou on integrated online pharmacy + chronic-care model targeting Chinese consumers.

TypeBroad incumbent
Description

US-listed DTC telehealth and online pharmacy platform focused on condition-specific care (weight management, mental health, dermatology). Comparable business model — DTC pharmacy + AI-enabled chronic care subscriptions — though operating in the US rather than China.

TypeEmerging player
Description

US-based DTC telehealth platform offering online consultations, prescriptions and medication delivery for chronic and recurring conditions. Comparable to Fangzhou's physician-mediated DTC pharmacy + chronic-care model, though at smaller scale and different geography.

TypeOthers
Description

Cloud infrastructure and AI solutions arm of Tencent serving Chinese healthcare providers and digital health platforms. Ecosystem partner to Fangzhou via the AI chronic-care solution, providing cloud and AI tooling comparable to what Fangzhou is building internally.

TypeEmerging player
Description

Chinese physician-community and chronic-disease management platform focused on connecting doctors with patients for condition-specific care programs. Comparable emerging player in the China AI-enabled chronic-care space, though smaller scale than Fangzhou.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fangzhou

Online Pharmacy and Digital Healthcarejianke.com

Fangzhou firmographics

Firmographics
Name
Fangzhou
Legal name
Fangzhou Inc.
Website
https://jianke.com
Company type
Public
Founded year
2015
Operating status
Operating
Ownership category
akta.pro rank

Fangzhou industry classification

Industry
Product category
Online Pharmacy and Digital Healthcare
NAICS
Pharmacies and Drug Retailers (456110), Pharmacies and Drug Retailers (45611)
SIC
Retail-Drug Stores And Proprietary Stores (5912), Services-Health Services (8000)
akta.pro industry
PRIMARYHLALAIAA
DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAH
Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

  • Online pharmacy retail
  • Chronic disease management
  • Telemedicine consultations
  • AI healthcare platform
  • Pharmaceutical e-commerce

Where Fangzhou is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Fangzhou business model

Business model
GTM type
B2C
Offering type
Digital Commerce or Content
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Online Pharmacy Retail: Direct-to-consumer online pharmacy sales through jianke.com platform. Customers purchase prescription and OTC medications, health products, medical devices, and supplements. Revenue generated from product sales with pricing varying by medication type and brand.
  2. Healthcare Services: Telemedicine consultation services connecting registered users with physicians. Platform facilitates online consultations, medication guidance, and health management services to registered users.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goIndividual product pricing varies by medication type and manufacturer

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Fangzhou product offering

Product offering

Core offering

Fangzhou operates a direct-to-consumer online pharmacy and digital healthcare platform selling prescription and OTC medications, health supplements, and medical devices through jianke.com. The platform provides telemedicine consultations with registered physicians and uses its proprietary XS LLM AI platform for chronic disease management. It serves over 59.8 million registered users and 282,000 physicians across China, primarily focused on chronic care patients requiring ongoing medication and monitoring.

Product overview

Fangzhou Inc. operates as a healthcare AI company with two main offerings: (1) AI-Powered Healthcare Solutions centered on the XS LLM Platform that automates patient and physician workflows for chronic disease management, and (2) 方舟健客 (Fangzhou Jianke) - a B2C online pharmacy ecosystem comprising the jianke.com e-commerce platform and the 健客医生 mobile app. The AI platform powers clinical decision support and healthcare automation, while the pharmacy platform provides online medication sales, health consultations, and patient monitoring services. The company serves over 59.8 million registered users with 282,000 registered physicians on its platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fangzhou Jianke Online Pharmacy (方舟健客网上药店) B2C online pharmacy platform where individual consumers nationwide can search, purchase, and receive prescription and OTC medications, health supplements, and medical devices, with pharmacist consultation support and prescription upload functionality.
  • Jianke Doctor (健客医生)

Quantifiable outcome

  • Revenue growth of 22.2% YoY reaching RMB 1.8245 billion in H1 2026
  • +2 more outcomes

Companies that use Fangzhou

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Fangzhou technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Fangzhou partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Tencent HealthcarecoreTechnology or Integration · 28 November 2025Fangzhou and Tencent Healthcare launched an AI-powered chronic disease management solution combining Fangzhou's clinical expertise with Tencent's cloud infrastructure. The platform enables personalized patient monitoring and early complication detection, streamlining clinical workflows and reducing professional workload while improving patient outcomes within China's chronic care ecosystem.
  • Novo NordiskcoreStrategic or Co-development Partner · 7 November 2025Fangzhou and Novo Nordisk launched an initiative for AI-powered diabetes and weight management solutions at the 8th China International Import Expo (CIIE) in Shanghai. Fangzhou was recognized as an 'Outstanding Strategic Health Ecosystem Partner' for digital innovation in chronic disease management. The strategic partnership aims to integrate Fangzhou's AI infrastructure with Novo Nordisk's therapies to shift from disease-focused treatment to proactive health management.
  • Multiple Pharmaceutical ManufacturerscoreStrategic or Co-development PartnerFangzhou has established strategic partnerships with major pharmaceutical manufacturers to ensure direct supply of authentic products. These partnerships enable competitive pricing, product exclusivity, and reliable supply chain management. The company claims to have agreements with numerous large-scale drug manufacturers for direct procurement.

Scale indicators8 records

Recent moves6 records

Fangzhou competitors and assessment

Company assessment

Direct peers

  • JD Health International: Hong Kong-listed Chinese online pharmacy and healthcare services platform with integrated telemedicine and chronic-disease management. Closest direct competitor to Fangzhou given overlapping DTC pharmacy model, AI-enabled healthcare ambitions and China-only footprint.
  • Alibaba Health Information Technology: HKEX-listed arm of Alibaba operating China's largest healthcare e-commerce platforms alongside telehealth and chronic-care services. Competes head-on with Fangzhou's jianke.com on drug retail assortment, pricing and AI-driven consumer health experiences.
  • Ping An Healthcare and Technology (Good Doctor): China-based online healthcare platform offering telemedicine consultations, chronic-care management and online pharmacy under the Ping An ecosystem. Highly relevant given comparable AI-enabled chronic-care strategy and integrated physician network.
  • WeDoctor (We Doctor / Tencent Trusted Doctor): Major Chinese digital healthcare platform combining hospital appointment booking, telemedicine and chronic-disease management. Overlaps with Fangzhou in AI chronic care, physician network and DTC patient services within China.
  • Dingdang Health (Dingdang Kuaiyao): China-focused online pharmacy with rapid-delivery prescription drug network and AI-powered chronic-care capabilities. Directly comparable to Fangzhou on DTC online pharmacy model and condition-specific digital health programs.
  • 111 Inc. (1药网 / Yi Yao Wang): NASDAQ-listed Chinese digital healthcare platform offering online pharmacy, B2B drug distribution and chronic-disease management. Comparable to Fangzhou on integrated online pharmacy + chronic-care model targeting Chinese consumers.

Broad incumbents

  • Hims & Hers Health: US-listed DTC telehealth and online pharmacy platform focused on condition-specific care (weight management, mental health, dermatology). Comparable business model — DTC pharmacy + AI-enabled chronic care subscriptions — though operating in the US rather than China.

Emerging players

  • Lemonaid Health: US-based DTC telehealth platform offering online consultations, prescriptions and medication delivery for chronic and recurring conditions. Comparable to Fangzhou's physician-mediated DTC pharmacy + chronic-care model, though at smaller scale and different geography.
  • Medlinker (医联): Chinese physician-community and chronic-disease management platform focused on connecting doctors with patients for condition-specific care programs. Comparable emerging player in the China AI-enabled chronic-care space, though smaller scale than Fangzhou.

Others

  • Tencent Healthcare: Cloud infrastructure and AI solutions arm of Tencent serving Chinese healthcare providers and digital health platforms. Ecosystem partner to Fangzhou via the AI chronic-care solution, providing cloud and AI tooling comparable to what Fangzhou is building internally.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Fangzhou compliance and trust

Trust signal

Compliance2 records

Fangzhou financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fangzhou leadership team

Management profile

Number of profiles

Fangzhou subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Fangzhou funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fangzhou M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fangzhou

What does Fangzhou do?

Fangzhou operates a direct-to-consumer online pharmacy and digital healthcare platform selling prescription and OTC medications, health supplements, and medical devices through jianke.com. The platform provides telemedicine consultations with registered physicians and uses its proprietary XS LLM AI platform for chronic disease management. It serves over 59.8 million registered users and 282,000 physicians across China, primarily focused on chronic care patients requiring ongoing medication and monitoring.

Is Fangzhou a public or private company?

Fangzhou is a public company. It is classified as public and is currently operating.

When was Fangzhou founded?

Fangzhou was founded in 2015.

Where is Fangzhou based?

Fangzhou is headquartered in Shanghai, China, in the Asia region.

How does Fangzhou make money?

Two revenue lines are on record. Online Pharmacy Retail is the primary driver. The others are healthcare Services.

Who are Fangzhou's main competitors?

Direct peers on record are JD Health International, Alibaba Health Information Technology, Ping An Healthcare and Technology (Good Doctor), WeDoctor (We Doctor / Tencent Trusted Doctor), Dingdang Health (Dingdang Kuaiyao) and 111 Inc. (1药网 / Yi Yao Wang). Hims & Hers Health is listed as a broad incumbent. Emerging players are Lemonaid Health and Medlinker (医联). Tencent Healthcare is listed as an others.

Does Fangzhou have an API?

No public API is recorded for Fangzhou.

What industry is Fangzhou in?

Fangzhou's product category is Online Pharmacy and Digital Healthcare. Its primary akta.pro industry code is HLALAIAA, DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription), with a secondary code of HLALAIAG, Medication Adherence & Therapy Management Platforms (refills, reminders, MTM). Its NAICS code is 456110 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialFangzhou And Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management InitiativeFangzhou and Baiyunshan Pharmaceutical launched an AI-powered chronic disease management initiative, combining Fangzhou's AI health tools with Baiyunshan's product portfolio. The partnership aims to develop integrated services including online assessments and prescription fulfillment. Fangzhou plans to expand its AI chronic disease services and work with industry partners to improve healthcare accessibility in China.FinancialContent Business PageFangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care InnovationFangzhou Inc. received the Outstanding Brand Award at the 14th Capital Power Annual Brand Awards for its AI-powered chronic disease services. The company's AI Health Manager and Medication Assistant support patients, while AI tools assist physicians. Fangzhou plans to continue investing in AI technology and expand its full-lifecycle health management offerings.YahooFangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care InnovationFangzhou Inc. received the Outstanding Brand Award at the 14th Capital Power Annual Brand Awards for its AI-powered chronic disease services. The company's AI Health Manager and Medication Assistant, powered by its XS LLM, aim to improve patient engagement and physician efficiency. It plans to continue investing in AI technology to expand its full-lifecycle health services.GlobeNewswireFangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care InnovationFangzhou Inc. received the Outstanding Brand Award at the 14th Capital Power Annual Brand Awards for its AI-powered chronic disease services. The company's AI Health Manager and Medication Assistant support patients, while AI tools assist physicians. It plans to continue investing in AI technology to enhance service offerings.The future of tradingFangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care InnovationFangzhou Inc. received the Outstanding Brand Award at the 14th Capital Power Annual Awards for its AI-powered chronic disease services. The company's AI Health Manager and Medication Assistant support patients, while AI tools assist physicians. It plans to continue investing in AI technology to enhance service offerings.MorningstarFangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care InnovationFangzhou Inc. received the Outstanding Brand Award at the 14th Capital Power Annual Awards for its AI-powered chronic disease services. The company's AI Health Manager and Medication Assistant support patients, while AI tools assist physicians. It plans to continue investing in AI to expand accessible, patient-centered care.Business & FinancialFangzhou Honored With Digital Intelligence Leadership Award At Tencent Summit, Expands Healthcare AI Partnership With Tencent HealthFangzhou received a Digital Intelligence Leadership Award at Tencent's annual summit, highlighting its AI+chronic disease services model. The company expanded its partnership with Tencent Health, integrating its XS LLM for AI-powered chronic disease management. It plans to continue strengthening this collaboration and expanding AI applications.FinancialContent Business PageFangzhou’s AI-Powered Supply Chain Platform Recognized in 2026 for Pharmaceutical Distribution Best PracticesFangzhou Inc. was recognized in the 2026 Collection of Best Practices for High-Quality Pharmaceutical Distribution Development for its AI-powered procurement and inventory platform. The recognition was announced at a conference in Guangzhou, and the company will continue refining its AI capabilities and chronic disease service model.GlobeNewswireFangzhou’s AI-Powered Supply Chain Platform Recognized in 2026 for Pharmaceutical Distribution Best PracticesFangzhou Inc. was recognized in the 2026 Collection of Best Practices for High-Quality Pharmaceutical Distribution Development for its AI-powered procurement and inventory platform. The recognition was announced at a conference in Guangzhou, and the company also advanced its AI chronic disease services strategy. It aims to share digital healthcare innovation with industry partners.The future of tradingFangzhou Showcases AI Chronic Care Solution at Fortune China 500 ForumFangzhou showcased its AI-powered chronic disease management solution at the 2026 Fortune China 500 Forum in Chengdu. The solution received recognition in Fortune China's Best Designs 2026 in September. Broader AI deployment in 2026 improved operational efficiency and reduced labor-intensive service costs.